Research summary
Research HubBPC-157
Clinical — 9 studies
BPC-157 is a 15-amino-acid peptide based on a sequence from a gastric juice protein, and its published research is largely preclinical. The sources cited here include two 2026 reviews of that research, a rat limb ischaemia study, and two small pilot reports in people.
Updated
Being studied for
- Musculoskeletal injury and pain models
- Limb ischaemia-reperfusion in rats
- Major vessel occlusion models
- Acetylcholinesterase inhibition assays
- Interstitial cystitis pilot studies
What the research shows
Nine items are cited, from 2022 to 2026, and only four report new data. Two are pilot reports in people: an uncontrolled study of intravesical BPC-157 in patients with interstitial cystitis, and an intravenous safety study in two healthy adults. The other two are laboratory work: a controlled rat study of lower-limb ischaemia-reperfusion injury and an enzyme study of acetylcholinesterase inhibition. The remaining five are two 2026 narrative reviews, one written for orthopaedic and sports medicine physicians; two pieces of commentary on earlier reviews; and a 2022 overview of vessel occlusion, Pringle manoeuvre and Budd-Chiari models.
The rat study reported that BPC-157 attenuated oxidative stress, apoptosis and inflammation in skeletal muscle after ischaemia-reperfusion, alongside angiogenic activity. The enzyme study found that BPC-157 and its hybrid analogues acted as reversible, competitive acetylcholinesterase inhibitors. The interstitial cystitis pilot measured symptom change in patients with moderate to severe disease who had not responded to pentosan polysulfate, and described itself as the first report of its kind. The infusion pilot reported no adverse effects in its two participants, while stating that further studies were needed to confirm safety.
The reviews set the context. The 2026 primer for orthopaedic and sports medicine physicians stresses the current lack of evidence for clinical use, and the tissue repair review points to inconsistent preparation standards, limited clinical validation and the need for rigorous controlled trials. The human data here amount to two pilots, one without a control arm and one with two participants, and neither can establish an effect. The rat study describes its own model only. The 2022 overview refers to earlier trials in ulcerative colitis and multiple sclerosis, but those trials are not among the sources cited here.
Published Research
Evidence profile
Preclinical, with limited uncontrolled human reports
9 cited publications
Evidence gap: No controlled human trial was identified. The human reports are small, uncontrolled pilots in single clinical settings; the remaining evidence is animal and in-vitro.
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Core evidence
The publications most central to understanding this compound.
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK et al. · The American journal of sports medicine · 2026
A review of injectable peptide therapy written for orthopaedic and sports medicine practitioners, which examines the evidence base behind BPC-157 and related peptides and characterises how far it supports clinical use.
“While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides.”
Context: A review, not new evidence. It is featured because it describes the size and quality of the evidence base.
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management
Yuan C et al. · International journal of molecular sciences · 2026
Reviews the published BPC-157 literature across tissue repair and pain models, covering reported mechanisms alongside preparation standards, clinical validation and regulatory constraints.
“BPC-157 remains a promising candidate for regenerative medicine, yet comprehensive evaluation is required before clinical translation can be recommended.”
Context: Reviews a largely preclinical literature and adds no human data.
Supporting evidence
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study
Lee E et al. · Alternative therapies in health and medicine · 2024
Population: Patients with moderate to severe interstitial cystitis not responding to pentosan polysulfate
A small uncontrolled pilot administering BPC-157 into the bladder and reporting symptom change. One of very few human reports involving this compound.
Context: A pilot with no control arm and few participants, in one clinical context. It cannot establish an effect and does not generalise.
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury
Yıldırım AK et al. · Scientific reports · 2026
Population: Rat model of lower-limb ischaemia-reperfusion injury
An animal study measuring oxidative stress, apoptosis, inflammation and angiogenesis markers in skeletal muscle after induced ischaemia-reperfusion injury.
Context: A rodent model. The findings describe that model and do not transfer to humans.
Additional indexed literature (5)
- Clinical · Mechanistic studySafety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Lee E et al. · Alternative therapies in health and medicine · 2025 · PMID 40131143
- Review · Mechanistic studyBPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185
Sikiric P et al. · Pharmaceuticals (Basel, Switzerland) · 2025 · PMID 41155565
- Review · Mechanistic studyConcerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT)
Whitehouse M · Inflammopharmacology · 2025 · PMID 40759852
- Review · Mechanistic studyCytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome
Sikiric P et al. · World journal of gastroenterology · 2022 · PMID 35125818
- Preclinical · Mechanistic studyBPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase
Jelińska J et al. · International journal of molecular sciences · 2026 · PMID 42278509
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Cobalt Peptides material. Citations verified against PubMed on 2026-09-29.
BPC-157 is a laboratory research compound that has not received approval as a medicine for use in people.
Notice
All information on this page is provided strictly for laboratory research and educational purposes only.